Nivalis begins second phase of cystic fibrosis drug study

Nivalis Therapeutics Inc. said it's begun the second phase of a study of its N91115 drug targeting cystic fibrosis. The Boulder biotech (Nasdaq: NVLS) said results of the study, which will examine the efficiency and safety of the drug, will be available in the second half of next year. "We are optimistic about its potential ability to improve lung function in people with cystic fibrosis," said Jon Congleton, president and chief executive officer of Nivalis, in a statement. Nivalis Therapeutics,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news